Sarah Boyce

Filings by Sarah Boyce span 6 companies, the busiest being Avidity Biosciences, Inc., OmniAb, Inc. and Ionis Pharmaceuticals Inc. Between 1 January 2016 and 18 September 2026, the trades on record add up to 39 filings.

In open-market terms, that means 1 purchase worth €57k on one side and 7 sales worth €3.0M on the other. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 13 share grants and 15 option exercises. 2026 to date brings no purchases and 2 sales.

The newest entry dates from 22 September 2026: a share grant of €985k, in Atrium Therapeutics, Inc. The latest purchase dates back some time: it was published 1,434 days ago, on 14 November 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.